Intuitive Surgical (NASDAQ:ISRG) Issues Earnings Results

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.76 by $0.17, Zacks reports. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $1.79 during midday trading on Thursday, reaching $608.66. 2,283,079 shares of the company's stock were exchanged, compared to its average volume of 1,821,864. The stock has a market capitalization of $216.79 billion, a PE ratio of 97.86, a price-to-earnings-growth ratio of 5.13 and a beta of 1.39. Intuitive Surgical has a 52-week low of $362.14 and a 52-week high of $616.00. The business's fifty day moving average price is $544.61 and its two-hundred day moving average price is $502.64.

Analyst Ratings Changes

A number of analysts recently issued reports on ISRG shares. Robert W. Baird raised their target price on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Stifel Nicolaus increased their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $549.00 to $630.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Evercore ISI reiterated a "cautious" rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Raymond James lifted their price target on Intuitive Surgical from $500.00 to $540.00 and gave the company an "outperform" rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $554.17.

Insider Buying and Selling at Intuitive Surgical

In other news, CFO Jamie Samath sold 108 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the transaction, the chief financial officer now owns 8,757 shares of the company's stock, valued at approximately $4,746,819.42. This trade represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 1,012 shares of the business's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $514.00, for a total value of $520,168.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company's stock, valued at approximately $2,830,084. This represents a 15.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,487 shares of company stock worth $22,590,975 in the last 90 days. 0.90% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.